Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineNeoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Neoadjuvant cemiplimab was administered to a total of 79 individuals. Upon independent review, a pathological complete response (51 percent; 95% confidence interval [CI], 39 to 62) was noted in 40 patients, and a pathological substantial response (13 percent; 95% CI, 6 to 22) was noted in 10 patients. These outcomes matched the abnormal reactions identified during the investigator’s examination. Fifty-four (54) patients (68%; 95% CI, 57 to 78) had an objective response on imaging, and 69 individuals (87%) experienced adverse events of any grade that happened throughout the course of the study, regardless of whether they were linked to the study treatment. Fourteen (14) participants (18%) experienced adverse events of grade 3 or higher during the research period.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form